Literature DB >> 28189566

Revisiting the role of Wnt/β-catenin signaling in prostate cancer.

Jeffrey A Schneider1, Susan K Logan2.   

Abstract

The androgen receptor (AR) is a widely accepted therapeutic target in prostate cancer and multiple studies indicate that the AR and Wnt/β-catenin pathways intersect. Recent genome-wide analysis of prostate cancer metastases illustrate the importance of the Wnt/β-catenin pathway in prostate cancer and compel us to reexamine the interaction of the AR and Wnt/β-catenin signaling pathways. This review includes newer areas of interest such as non-canonical Wnt signaling and the role of Wnts in prostate cancer stem cells. The effort to develop Wnt modulating therapeutics, both biologics and small molecules, is also discussed.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Androgen receptor; Prostate cancer; Wnt signaling; β-catenin

Mesh：

Substances：

Year:  2017        PMID： 28189566      PMCID： PMC5550366          DOI： 10.1016/j.mce.2017.02.008

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN： 0303-7207            Impact factor:   4.102


  83 in total

Review 1.  Stem cells in prostate cancer initiation and progression.

Authors:  Devon A Lawson; Owen N Witte
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

2.  Structural basis of coactivation of liver receptor homolog-1 by β-catenin.

Authors:  Fumiaki Yumoto; Phuong Nguyen; Elena P Sablin; John D Baxter; Paul Webb; Robert J Fletterick
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-20       Impact factor: 11.205

3.  An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.

Authors:  Foster C Gonsalves; Keren Klein; Brittany B Carson; Shauna Katz; Laura A Ekas; Steve Evans; Robert Nagourney; Timothy Cardozo; Anthony M C Brown; Ramanuj DasGupta
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-10       Impact factor: 11.205

4.  LEF1 identifies androgen-independent epithelium in the developing prostate.

Authors:  Xinyu Wu; Garrett Daniels; Ellen Shapiro; Kun Xu; Hongying Huang; Yirong Li; Susan Logan; M Alba Greco; Yi Peng; Marie E Monaco; Jonathan Melamed; Herbert Lepor; Irina Grishina; Peng Lee
Journal:  Mol Endocrinol       Date:  2011-04-28

5.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

6.  Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells.

Authors:  X Yang; M-W Chen; S Terry; F Vacherot; D L Bemis; J Capodice; J Kitajewski; A de la Taille; M C Benson; Y Guo; R Buttyan
Journal:  Oncogene       Date:  2006-02-13       Impact factor: 9.867

7.  Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity.

Authors:  Thomas R Salas; Jeri Kim; Funda Vakar-Lopez; Anita L Sabichi; Patricia Troncoso; Guido Jenster; Akira Kikuchi; Shao-Yong Chen; Lirim Shemshedini; Milind Suraokar; Christopher J Logothetis; John DiGiovanni; Scott M Lippman; David G Menter
Journal:  J Biol Chem       Date:  2004-02-24       Impact factor: 5.157

8.  Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.

Authors:  Wenyan Lu; Cuihong Lin; Michael J Roberts; William R Waud; Gary A Piazza; Yonghe Li
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

9.  Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis.

Authors:  S H Lee; R Luong; D T Johnson; G R Cunha; L Rivina; M L Gonzalgo; Z Sun
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

10.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.

Authors:  David T Miyamoto; Yu Zheng; Ben S Wittner; Richard J Lee; Huili Zhu; Katherine T Broderick; Rushil Desai; Douglas B Fox; Brian W Brannigan; Julie Trautwein; Kshitij S Arora; Niyati Desai; Douglas M Dahl; Lecia V Sequist; Matthew R Smith; Ravi Kapur; Chin-Lee Wu; Toshi Shioda; Sridhar Ramaswamy; David T Ting; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber
Journal:  Science       Date:  2015-09-18       Impact factor: 47.728
View more
  42 in total

1.  Epigenetic analysis identifies factors driving racial disparity in prostate cancer.

Authors:  Richa Rai; Shalini S Yadav; Heng Pan; Irtaza Khan; James O'Connor; Mohammed Alshalalfa; Elai Davicioni; Emanuela Taioli; Olivier Elemento; Ashutosh K Tewari; Kamlesh K Yadav
Journal:  Cancer Rep (Hoboken)       Date:  2018-12-13

2.  Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of β-catenin in prostate cancer cells.

Authors:  Kati Erdmann; Knut Kaulke; Christiane Rieger; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2017-07-24       Impact factor: 4.553

3.  AT-rich interaction domain 5A regulates the transcription of interleukin-6 gene in prostate cancer cells.

Authors:  Wataru Ikeuchi; Yuriko Wakita; Guoxiang Zhang; Chun Li; Keiichi Itakura; Takahiro Yamakawa
Journal:  Prostate       Date:  2021-10-11       Impact factor: 4.104

4.  Role of lupeol in chemosensitizing therapy-resistant prostate cancer cells by targeting MYC, β-catenin and c-FLIP: in silico and in vitro studies.

Authors:  Homa Fatma; Santosh Kumar Maurya; Akhilesh Kumar Maurya; Nidhi Mishra; Hifzur R Siddique
Journal:  In Silico Pharmacol       Date:  2022-09-04

Review 5.  Dual contribution of the mTOR pathway and of the metabolism of amino acids in prostate cancer.

Authors:  Alejandro Schcolnik-Cabrera; Daniel Juárez-López
Journal:  Cell Oncol (Dordr)       Date:  2022-08-29       Impact factor: 7.051

6.  Long non-coding RNA MEG3 promotes the proliferation of glioma cells through targeting Wnt/β-catenin signal pathway.

Authors:  X Gong; M Huang
Journal:  Cancer Gene Ther       Date:  2017-10-13       Impact factor: 5.987

7.  Direct interaction of β-catenin with nuclear ESM1 supports stemness of metastatic prostate cancer.

Authors:  Ke-Fan Pan; Wei-Jiunn Lee; Chun-Chi Chou; Yi-Chieh Yang; Yu-Chan Chang; Ming-Hsien Chien; Michael Hsiao; Kuo-Tai Hua
Journal:  EMBO J       Date:  2020-12-21       Impact factor: 11.598

8.  KAT6A, a novel regulator of β-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1.

Authors:  Wenxue Liu; Zhiyan Zhan; Meiying Zhang; Bowen Sun; Qiqi Shi; Fei Luo; Mingda Zhang; Weiwei Zhang; Yanli Hou; Xiuying Xiao; Yanxin Li; Haizhong Feng
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

9.  ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-β-catenin signaling.

Authors:  Vincent C Pai; Chung-Chi Hsu; Tze-Sian Chan; Wen-Ying Liao; Chih-Pin Chuu; Wei-Yu Chen; Chi-Rong Li; Ching-Yu Lin; Shu-Pin Huang; Li-Tzong Chen; Kelvin K Tsai
Journal:  Oncogene       Date:  2018-09-28       Impact factor: 8.756

10.  ZEB1 serves an oncogenic role in the tumourigenesis of HCC by promoting cell proliferation, migration, and inhibiting apoptosis via Wnt/β-catenin signaling pathway.

Authors:  Liang-Yun Li; Jun-Fa Yang; Fan Rong; Zhi-Pan Luo; Shuang Hu; Hui Fang; Ying Wu; Rui Yao; Wei-Hao Kong; Xiao-Wen Feng; Bang-Jie Chen; Jun Li; Tao Xu
Journal:  Acta Pharmacol Sin       Date:  2021-01-29       Impact factor: 7.169
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.